Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Oracle Corporation Q3 FY2026 Earnings Call - AI infrastructure demand converts into profitable recurring cloud revenue
Oracle reported a blowout Q3, with both organic total revenue and organic non-GAAP EPS up more than 20% in USD, a first in over 15 years. The quarter’s story is clear, AI demand is not theoretical any...
- Q3 was a standout, Oracle reported organic total revenue and organic non-GAAP EPS growth above 20% in USD, the first time in over 15 years.
- AI infrastructure revenue grew 243% year over year, multi-cloud database revenue grew 531% year over year, signaling outsized demand for Oracle’s AI and data services.
- Reported RPO reached $553 billion, management attributes much of the increase to large-scale AI contracts, indicating demand currently exceeds supply.
- +15 more takeaways
Motorsport Games Inc. Q4 & Full Year 2025 Earnings Call - Turnaround: Le Mans Ultimate and Race Control Fuel Profitability
Motorsport Games presented a clear turnaround: revenue growth, sustained profitability, and improving liquidity driven largely by Le Mans Ultimate and the Race Control platform. Management highlighted...
- Q4 2025 revenue was $3.8 million, up 95% year over year, driven primarily by digital sales of Le Mans Ultimate and DLC.
- Full year 2025 revenue totaled $11.3 million, a 30% increase versus 2024, with Le Mans franchise sales up $5.8 million and Race Control contributing $1.2 million.
- Net income was $0.8 million in Q4 2025 versus a $2.9 million loss in the year-earlier quarter; full year 2025 net income was $6.8 million versus a $3.1 million loss in 2024.
- +12 more takeaways
Blend Labs, Inc. Q4 2025 Earnings Call - Autopilot Launch and Return to Profitability
Blend closed 2025 with a tidy quarter, $32.4 million in revenue and $5.4 million in non-GAAP operating income, and a balance sheet that looks deliberate: zero debt and roughly $68.3 million in cash an...
- Q4 revenue was $32.4 million, with non-GAAP operating income of $5.4 million, implying a 17% non-GAAP operating margin for the quarter.
- Blend ended Q4 with $68.3 million in cash and marketable securities, and zero debt, and reported positive free cash flow of $1.3 million for Q4, $2.8 million for the full year 2025.
- The board authorized a new $50 million share buyback program; Blend repurchased 5.1 million shares in Q4 for about $15-16 million, completing a prior $25 million program.
- +12 more takeaways
Finance of America Q4 and Full Year 2025 Earnings Call - Adjusted earnings power scales, guiding $4.25-$4.75 for 2026
Finance of America closed 2025 with a clear message, not a mystery. Adjusted results show the business scaling: full-year adjusted net income rose to $74 million ($3.04 per share), adjusted EBITDA hit...
- Full-year 2025 GAAP net income was $110 million, or $5.04 per basic share, a 175% improvement vs. 2024.
- Full-year 2025 adjusted net income was $74 million, or $3.04 per share, up 429% vs. 2024 and above prior guidance.
- Adjusted EBITDA for 2025 totaled $143 million, a 138% year-over-year increase, signaling operating leverage as the platform scales.
- +12 more takeaways
Concrete Pumping Holdings Q1 2026 Earnings Call - Data center strength and pricing offset soft housing, guidance left intact
Concrete Pumping reported a clean, if cautious, start to fiscal 2026. Revenue rose 5% to $90.6 million and adjusted EBITDA climbed 6% to $18.0 million, driven by a U.S. commercial rebound led by data ...
- Revenue up 5% year over year to $90.6 million, with adjusted EBITDA up 6% to $18.0 million, showing early-cycle resilience despite a cautious guide.
- U.S. Concrete Pumping revenue rose 5% to $59.9 million, led by commercial and infrastructure work, notably data center projects and chip plants.
- Eco-Pan Concrete Waste Management revenue grew 8% to $18.1 million and delivered 20% adjusted EBITDA growth, underscoring its defensive, scalable cash flow profile.
- +14 more takeaways
Shoulder Innovations Q4 2025 Earnings Call - Accelerating surgeon adoption and robotics push, but operating losses widen as company scales
Shoulder Innovations closed 2025 with clear commercial momentum: Q4 revenue of $14.4 million, up 65% year over year, and full-year revenue of $47.3 million, up 50%. Implant volumes and surgeon adoptio...
- Top-line acceleration: Q4 2025 revenue $14.4M, +65% YoY; full-year 2025 revenue $47.3M, +50% YoY, driven by increased surgeon adoption and implant volume growth.
- Implant volume jump: Q4 implants 1,976 units, +62% YoY; full-year 6,506 units, +50% YoY — unit growth is the primary revenue driver.
- Surgeon base expansion: Core and contender surgeon count reached 134 at year-end, a 61% increase YoY; company will report this metric annually going forward.
- +12 more takeaways
Evolv Technologies Q4 2025 Earnings Call - Guide Raised as Subscription ARR Momentum Accelerates
Evolv closed 2025 with clear momentum, trading near-term margin pain for longer-term recurring revenue and cash value. Q4 revenue beat with $38.5 million, full-year revenue reached $145.9 million, and...
- Q4 2025 revenue $38.5 million, up 32% year-over-year; full-year revenue $145.9 million, up 40% year-over-year.
- Ending ARR $120.5 million, up 21% year-over-year, with management expecting ARR growth to accelerate in 2026 and to outpace revenue growth.
- Company raised 2026 revenue guidance to $172 million to $178 million, up from prior $160 million to $165 million guidance.
- +12 more takeaways
Skye Bioscience Q4 2025 Earnings Call - Initiating higher-dose expansion after 200 mg underexposed peripheral tissues
Skye pitched a straightforward pivot: the 200 mg weekly nimacimab dose was safe but underexposed key peripheral tissues, so the company is fast-tracking a Part C expansion with higher IV doses to reac...
- CBeyond combination signal: nimacimab plus semaglutide showed a clinically meaningful 3% incremental weight loss versus semaglutide alone at 26 weeks, with no plateau observed.
- 52-week durability: the combination arm achieved 22.3% mean weight loss at 52 weeks in the extension, one of the first reported clinical CB1 plus GLP-1 datasets.
- Safety profile: nimacimab 200 mg weekly demonstrated placebo-like tolerability through 52 weeks, with no nimacimab-associated neuropsychiatric signal and no additive GI burden when combined with semaglutide.
- +11 more takeaways
Westrock Coffee Company Q4 2025 Earnings Call - Construction Over, Conway Fully Commercialized, FCF Positive by 2H 2026
Westrock closed 2025 with a clean pivot from heavy build to full-scale operations. The company reported record results, with consolidated adjusted EBITDA of $69.7 million, and Q4 adj. EBITDA of $23 mi...
- Consolidated adjusted EBITDA for fiscal 2025 was $69.7 million, up 48% year‑over‑year; Q4 adj. EBITDA was $23.0 million, up 72% YoY.
- Management expects consolidated adjusted EBITDA of $90 million to $100 million for 2026, implying 29% to 44% growth year over year.
- Company expects to be free cash flow positive after capex and debt service in the second half of 2026, as capex falls to ~ $30 million for 2026.
- +12 more takeaways
TransAct Technologies Q4 2025 Earnings Call - Pivot to Software-Driven FST Growth After BOHA! Source Code Acquisition
TransAct closed 2025 on momentum, with hardware placements and a strong labels quarter underpinning a deliberate pivot toward software-led growth in food service technology. Management is leveraging i...
- TransAct sold 1,434 BOHA! terminals in Q4, finishing 2025 with 7,317 terminals sold, a 36% increase versus 2024 (5,371).
- Total net sales for Q4 were $11.5 million, up 12% year-over-year; full-year 2025 sales were $51.5 million, up 19% from 2024.
- FST (food service technology) net sales were $4.8 million in Q4, up 12% year-over-year; full-year FST sales were $19.3 million, up 20% versus 2024.
- +13 more takeaways